DOSE: A Busy Year for an ADHD Company Built Differently

Most productivity apps assume the hard part is remembering what to do. For people with ADHD, the hard part is often starting, staying regulated and getting through the moment when everything feels like too much.

DOSE is built for those moments. We invested in DOSE, and the last few months have been a good illustration of why.

The last few months, in order

July 2026. DOSE placed in the top 5 of LvlUp's Zendesk CX Challenge, a six-week program for portfolio companies.

September 14, 2026. DOSE won first place at the Stanford GSB LISA Cohort 12 Pitchfest.

This quarter. Dr. Olivia Skalski joined as Chief Clinical Officer, bringing licensed psychologist oversight to DOSE's clinical design and safety. The team also launched IGNITE, which uses AI to turn a task someone is avoiding into one small first step; Today's List, a focused view of what actually matters today; and a Medication Tracker that uses official FDA drug label data and was reviewed by Dr. Skalski.

Where the business stands

DOSE is profitable, with $21K in monthly recurring revenue and about $189K in annual run-rate. The team reports a 30% conversion rate and has grown without paid advertising. Alongside the app, DOSE has delivered more than 1,400 coaching sessions and runs a free monthly coaching class open to the public.

Why we like the approach

Most apps in the category focus on planners and reminders. DOSE goes further into the emotional side of ADHD, with tools for regulating intense feelings, handling rejection sensitivity and reframing unhelpful thoughts, plus an AI companion that remembers context over time.

The clinical leadership matters too. In mental health, credibility is earned slowly, and having a licensed psychologist shaping the product gives DOSE a foundation many consumer apps lack.

What comes next

Today DOSE's users are mostly women, and one of the team's priorities is reaching more men with ADHD, who are often less likely to seek support. The company is also building a referral pathway to diagnosis, since DOSE supports people with ADHD but doesn't diagnose it, and exploring employer and benefits channels.

In Steev's words

"LvlUp Ventures has been one of the most valuable parts of DOSE's journey as an early-stage company. The team is genuinely invested in founders, and it shows in how accessible and practical the support is."

Figures are founder-reported, from DOSE's October 2026 Quarterly Founder Update, and shared with the company's permission.